Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension: An 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial

Clinical Therapeutics

Volumn 30, Issue 5, 2008, Pages 845-857

  Kim, Sung Ai ^a   Park, Sungha ^a   Chung, Namsik ^a   Lim, Do Sun ^b   Yang, Joo Young ^c   Oh, Byung Hee ^d   Tahk, Seung Jea ^e   Ahn, Tae Hoon ^f  

^a Yonsei University College of Medicine   (South Korea)

^b College of Medicine   (South Korea)

^c National Health Insurance Corporation   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e Ajou University Medical CentSuwon   (South Korea)

^f Gachon University   (South Korea)

Author keywords

amlodipine; hypertension; nicotinate; racemic

Indexed keywords

ALANINE AMINOTRANSFERASE; AMLODIPINE BESYLATE; AMLODIPINE MALEATE; AMLODIPINE NICOTINATE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; PARACETAMOL; PLACEBO; URIC ACID;

ADULT; AGE DISTRIBUTION; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ARTICLE; ASIAN; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FACIAL FLUSHING; FATIGUE; FEMALE; FLUID THERAPY; FOOT EDEMA; FRACTURE; HEADACHE; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RATE; HEART RATE VARIABILITY; HIGH RISK PATIENT; HORDEOLUM; HOT FLUSH; HUMAN; HYPERTENSION; LYMPHOCYTIC PANNICULITIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; PANNICULITIS; PARESTHESIA; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; RACEMIC MIXTURE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SOUTH KOREA; SPUTUM; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; URIC ACID BLOOD LEVEL; URINARY FREQUENCY; WEIGHT GAIN; XEROPHTHALMIA; XEROSTOMIA;

ADULT; AGED; AMLODIPINE; ASIAN CONTINENTAL ANCESTRY GROUP; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NIACIN; STEREOISOMERISM;

EID: 44849126989     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2008.05.013     Document Type: Article

References (26)

1. Tucker G. Chiral switches. Lancet 355 (2000) 1085-1087
2. Mansfield P., Henry D., and Tonkin A. Single-enantiomer drugs: Elegant science, disappointing effects. Clinical Pharmacokinet 43 (2004) 287-290
3. Adik-Pathak L. Chiral molecules in hypertension: Focus on S-amlodipine. J Assoc Physicians India 52 (2004) 187-188
4. Rentsch K. The importance of stereoselective determination of drugs in the clinical laboratory. J Biochem Biophys Methods 54 (2002) 1-9
5. Agranat I., Caner H., and Caldwell J. Putting chirality to work: The strategy of chiral switches. Nat Rev Drug Discov 1 (2002) 753-768
6. Graul A., Castañer R., and Castañer J. Esomeprazole magnesium. H+/K+-ATPase inhibitor antiulcer treatment of GERD. Drugs Future 24 (1999) 1178-1183
7. Handley D., Morley J., and Vaickus L. Levalbuterol hydrochloride. Expert Opin Investig Drugs 7 (1998) 2027-2041
8. Mayer J., and Testa B. Pharmacodynamics, pharmacokinetics and toxicity of ibuprofen enantiomers. Drugs Future 22 (1997) 1347-1366
9. Zhang X., Loke K., Mital S., et al. Paradoxical release of nitric oxide by an L-type calcium channel antagonist, the R+ enantiomer of amlodipine. J Cardiovasc Pharmacol 39 (2002) 208-214
10. Lee H., Kang H., Koo B., et al., for the Amostar Study Investigators. Clinic blood pressure responses to two amlodipine salt formulations, adipate and besylate, in adult Korean patients with mild to moderate hypertension: A multicenter, randomized, double-blind, parallel-group, 8-week comparison. Clin Ther 27 (2005) 728-739
11. Park S., Chung N., Kwon J., et al. Results of a multicenter, 8-week, parallel-group, randomized, double-blind, doubledummy, Phase III clinical trial to evaluate the efficacy and tolerability of amlodipine maleate versus amlodipine besylate in Korean patients with mild to moderate hypertension. Clin Ther 27 (2005) 441-450
12. Hong S., Ahn T., Baek S., et al. Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebocontrolled, parallel-group, 8-week follow-up, noninferiority trial [published correction appears in Clin Ther. 2006;28:1245]. Clin Ther 28 (2006) 537-551
13. Park J., Kim K., Park P., et al. Comparative pharmacokinetic and pharmacodynamic characteristics of amlodipine besylate and amlodipine nicotinate in healthy subjects. Int J Clin Pharmacol Ther 44 (2006) 641-647
14. Kim S., Kim Y., Lim D., et al., for the Korean Multicenter Amlodipine Study Investigators. Results of a phase III, 8-week, multicenter, prospective, randomized, doubleblind, parallel-group clinical trial to assess the effects of amlodipine camsylate versus amlodipine besylate in Korean adults with mild to moderate hypertension. Clin Ther 29 (2007) 1924-1936
15. Park J., Kim K., Park P., et al. Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: A randomized, open-label, two-period, comparative, crossover study. Clin Ther 28 (2006) 1837-1847
16. US Food and Drug Administration. Guidance: Statistical procedure for bioequivalence studies using standard 2-treatment cross-over design: Statement under 21 CFR 10.9 (1992), US Dept of Health and Human Services, Rockville, Md
17. Williams B., Poulter N., Brown M., et al., for the British Hypertension Society. Guidelines for management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 18 (2004) 139-185
18. Byyny R., Shannon T., Schwartz L., et al. Efficacy and safety of nifedipine coat-core versus amlodipine in patients with mild to moderate essential hypertension: Comparison of 24-hour mean ambulatory diastolic blood pressure. J Cardiovasc Pharmacol Ther 2 (1997) 77-84
19. Mallion J., Chastang C., and Unger P. Efficacy and safety of a fixed lowdose perindopril/indapamide combination in essential hypertension. A randomised controlled study. Clin Exp Hypertens 22 (2000) 23-32
20. Laufen H., and Leitold M. Enantioselective disposition of oral amlodipine in healthy volunteers. Chirality 6 (1994) 531-536
21. Luksa J., Josic D., Kremser M., et al. Pharmacokinetic behaviour of R-(+)-and S-(-)-amlodipine after single enantiomer administration. J Chromatogr B Biomed Sci Appl 703 (1997) 185-193
22. Gustafsson D. Microvascular mechanisms involved in calcium antagonist edema formation. J Cardiovasc Pharmacol 10 Suppl 1 (1987) S121-S131
23. Salmasi A., Belcaro G., and Nicolaides A. Impaired venoarteriolar reflex as a possible cause for nifedipineinduced ankle oedema. Int J Cardiol 30 (1991) 303-307
24. Messerli F. Vasodilatory edema: A common side effect of antihypertensive therapy. Am J Hypertens 14 (2001) 978-979
25. Beckey C., Lundy A., and Lutfi N. Lercanidipine in the treatment of hypertension. Ann Pharmacother 41 (2007) 465-473
26. Pathak L., Hiremath P., Kerkar, and Manade V. Multicentric, clinical trial of S-amlodipine 2.5 mg versus amlodipine 5 mg in the treatment of mild to moderate hypertension-a randomized, double-blind clinical trial. J Assoc Physicians India 52 (2004) 197202